A Phase 2/3 interventional study of SEP-363856 50 mg and SEP-363856 75 mg in Schizophrenia, sponsored by Sumitomo Pharma Co., Ltd.. Terminated at 54 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Sumitomo Pharma Co., Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.
Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 12th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 2/3, and was the 13th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 3 · Phase 3 10
First in 2013; this study’s year is marked. 2 started in 2021.
This study's enrollment of 83 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 83 across the 23 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 23 have an industry lead sponsor. The 3 most frequent:
Sumitomo Pharma Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 26th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2021, is the only one in phase 2/3, and was the 37th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing SEP-363856 in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.
A Phase 2/3 Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Patients with Schizophrenia, Followed by an Open-label Extension Phase.
The double-blind phase is to evaluate the efficacy and safety of 2 doses of SEP-363856 (50 and 75 mg/day) versus placebo over 6 weeks in acutely psychotic patients with schizophrenia. This phase is projected to randomize approximately 480 subjects to 3 treatments (SEP-363856 50 mg/day, SEP-363856 75 mg/day, placebo) in a 1:1:1 ratio. The completers of the double-blind phase will be able to enroll into the 12-week open-label phase during which the long term safety and effectiveness of-SEP 363856 will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have an acute exacerbation of psychotic symptoms (no longer than 2 months prior to providing informed consent for this study). The acute exacerbation should include:
a. Marked deterioration of functioning in one or more areas, such as occupational, social, or personal care or hygiene.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the SEP-363856 50 mg/day group will receive the assigned dose of SEP-363856 50 mg/day throughout the double-blind phase.
Drug: SEP-363856 50 mg
Subjects randomized to the SEP-363856 75 mg/day group will receive SEP-363856 50 mg/day on Day 1 through Day 3 and then the assigned dose of SEP-363856 75 mg/day thereafter.
Drug: SEP-363856 75 mg
Subjects randomized to the placebo group will receive placebo throughout the double-blind phase.
Drug: Placebo
Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Week 6
PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.
Time frame: Week 6
Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Week 6
The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.
Time frame: Week 6
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2021 to primary completion in Oct 2023, 30 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SEP-363856